Oncología hepática (BCLC)

Publicaciones destacadas

Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules

Sanduzzi-Zamparelli, M; Mariño, Z; Lens, S; Sapena, V; Iserte, G;

(...)

Forner, A; Torres, F; Bruix, J; Forns, X; Reig, M.

Referencia:
Journal Of Hepatology 2022.
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Sapena, Victor; Enea, Marco; Torres, Ferran; Celsa, Ciro; Rios, Jose;

(...)

Trevisani, Franco; Camma, Calogero; Bruix, Jordi; Cabibbo, Giuseppe; Reig, Maria.

Referencia:
Gut 2022.
Regorafenib efficacy after sorafenib in patients with recurrent HCC after liver transplantation: a retrospective study

Iavarone, M; Invernizzi, F; Ivanics, T; Mazza, S; Zavaglia, C;

(...)

Wörns, MA; Bruix, J; Sapisochin, G; Lampertico, P; Reig, M.

Referencia:
Liver Transplantation 2021.
Antiviral therapy in the palliative setting of HCC (BCLC B and C)

Reig, M; Cabibbo, G;

Referencia:
Journal Of Hepatology 2021.
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

Corominas, Josep; Sapena, Victor; Sanduzzi-Zamparelli, Marco; Millan, Cristina; Samper, Esther;

(...)

Munoz-Martinez, Sergio; Forner, Alejandro; Bruix, Jordi; Boix, Loreto; Reig, Maria.

Referencia:
Cancers 2021.
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S;

(...)

Varela M; Wörns MA; Bruix J; Lampertico P; Reig M .

Referencia:
American Journal Of Transplantation 2019.
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules

Marino, Zoe; Darne, Anna; Lens, Sabela; Sapena, Victor; Diaz, Alba;

(...)

Ayuso, Carmen; Rios, Jose; Forns, Xavier; Bruix, Jordi; Reig, Maria.

Referencia:
Journal Of Hepatology 2019.
New trials and results in systemic treatment of HCC.

Reig M; da Fonseca LG; Faivre S ;

Referencia:
Journal Of Hepatology 2018.
Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.

Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;

(...)

Huertas C; Minguez B; Ayuso C; Bruix J; Reig M .

Referencia:
Hepatology 2018.